false
0001946563
DC
0001946563
2024-08-12
2024-08-12
0001946563
SXTP:CommonStockParValue0.0001PerShareMember
2024-08-12
2024-08-12
0001946563
SXTP:WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember
2024-08-12
2024-08-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
August 12, 2024
60 DEGREES PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-41719 |
|
45-2406880 |
(State or other jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification Number) |
1025 Connecticut Avenue NW Suite 1000,
Washington, D.C. |
|
20036 |
(Address of registrant’s principal executive office) |
|
(Zip code) |
(202) 327-5422
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
☐ | Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
Title of each class |
|
Trading symbol(s) |
|
Name of each exchange
on which registered |
Common Stock, par value $0.0001 per share |
|
SXTP |
|
The Nasdaq Stock Market LLC |
|
|
|
|
|
Warrants, each warrant to purchase one share of Common Stock |
|
SXTPW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events.
On August 12, 2024, 60 Degrees Pharmaceuticals,
Inc. (the “Company”) issued a press release announcing that it granted the University of Kentucky a right of reference to
the Company’s new drug application for ARAKODA® (tafenoquine). The right of reference will allow the U.S. Food and Drug Administration
(the “FDA”) to review clinical efficacy and safety data, non-clinical data and chemistry, manufacturing and control information
on ARAKODA® as the FDA reviews protocols and new Investigational New Drug application submissions related to the University of Kentucky’s
investigational SJ733 Phase IIb program. The Company’s press release is filed as Exhibit 99.1 to this Current Report on Form 8-K
and is incorporated herein by reference.
The information set forth under this Item 8.01,
including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934,
as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific
reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
The following exhibits are being filed herewith:
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
60 DEGREES PHARMACEUTICALS, INC. |
|
|
Date: August 14, 2024 |
By: |
/s/ Geoffrey Dow |
|
Name: |
Geoffrey Dow |
|
Title: |
Chief Executive Officer and President |
2
Exhibit 99.1
60 Degrees Pharma Provides University of Kentucky with Right of
Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
Published
Aug 12, 2024 9:12am EDT
| 1. | University of Kentucky will commence a Phase IIb clinical study
of drug development candidate SJ733 for treatment of vivax malaria. |
| 2. | SJ733 will be combined with a single dose of tafenoquine
in the study. |
| 3. | The right of reference allows FDA to review 60 Degrees Pharma’s
regulatory file when the agency evaluates new study protocols for the SJ733-tafenoquine Phase IIb program. |
WASHINGTON, D.C., Aug.
12, 2024 -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company” or “60 Degrees Pharma”), a
pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it has granted the University
of Kentucky a right of reference to the Company’s new drug application (“NDA”) for ARAKODA® (tafenoquine).
ARAKODA is the Company’s anti-malarial
approved by the U.S. Food and Drug Administration (“FDA”) in 2018, indicated for the prophylaxis of malaria in patients aged
18 years of age and older.
The right of reference will allow FDA to review
clinical efficacy and safety data, non-clinical data, and chemistry, manufacturing and control information on ARAKODA as the agency reviews
protocols and new Investigational New Drug (“IND”) application submissions related to the University of Kentucky’s investigational
SJ733 Phase IIb program.
SJ733 is an oral ATP4 inhibitor of Plasmodium,
which has been shown to have a favorable safety profile and rapid anti-parasitic effect. The Phase IIb study being conducted by the University
of Kentucky and Eisai Co. Ltd. (“Eisai”) will combine SJ733 with tafenoquine – the active ingredient in ARAKODA
– to evaluate the safety, tolerability, and pharmacokinetics of a single-dose combination of the two drugs. The trial is funded
by the Global Health Innovative Technology Fund. The current state-of-the-art treatment for vivax malaria is a combination of tafenoquine
and chloroquine administered over three days; however, resistance of P. vivax to chloroquine is widespread in some parts of the
world.
“Innovations in treating P. vivax
malaria, which infects an estimated 14 million people a year, have been limited in recent decades,” said Dr. R. Kip Guy, principal
investigator on the Phase IIb study, and Professor and Dean of the University of Kentucky College of Pharmacy. “The upcoming study
of SJ733 combined with tafenoquine has the potential to pave the way for very meaningful improvement in malaria treatment around
the world.”
60 Degrees Pharma will supply tafenoquine
and placebos as study drugs in the University of Kentucky Phase IIb trial.
Tafenoquine is approved for malaria
prophylaxis in the United States under the product name ARAKODA®. The safety of the approved regimen of tafenoquine
for malaria prophylaxis has been assessed in five separate randomized, double-blind, active comparator or placebo-controlled trials for
durations of up to six months.
About the SJ733 Phase IIb Clinical Trial
at University of Kentucky
The overall objective of the Phase IIb study is to examine the clinical
safety and efficacy of the combination of SJ733 and TQ for radical cure of P. uncomplicated P. vivax malaria in adults with
a 1, 2, or 3-day schedule of the SJ733-tafenoquine combination. The purpose is to develop an SJ733-TQ combination drug suitable
for treatment of all patients with uncomplicated P. vivax malaria. The targeted results for this study are data that support 1
to 3 doses of an SJ733-TQ fixed-dose combination for radical cure of P. vivax mono-infected patients. This will set the stage for
subsequent pivotal Phase 3 studies.
SJ733 is a PfATP4 inhibitor that meets criteria for treatment
of uncomplicated malaria. Three clinical trials of SJ733 have been completed. Phase I examined safety and pharmacokinetics of SJ733. Phase
I tested pharmacodynamics in the human challenge model. Phase II (NCT04709692) determined the parasite reduction ratio, parasite reduction
half-life and minimum inhibitory concentration of SJ733 in adults with uncomplicated malaria and assessed the exposure-response relationship
(PK/PD). Current Phase Ia, Ib, and IIa human data show an excellent safety profile and tolerability, good oral availability, and
moderate drug clearance.
Eisai and the University of Kentucky have collaboratively designed
the Phase IIb study and supportive non-clinical safety and pharmacokinetics studies, which will be contracted to rigorously qualified
CROs and overseen by Eisai’s subject matter experts. Eisai will manage the manufacture of a new batch of SJ733 clinical trial material,
as well as oversee conduct of the supportive non-clinical safety and pharmacokinetics studies.
The University of Kentucky will oversee the regulatory filings to amend
the current US-FDA IND (held by Professor Guy) for development of SJ733 and the Phase IIb clinical trial work, including the local ethics
and regulatory submissions.
About ARAKODA®
(tafenoquine)
Tafenoquine was
discovered by Walter Reed Army Institute of Research. Tafenoquine was approved for malaria prophylaxis in 2018 in the
United States as ARAKODA® and in Australia as KODATEF®. Both were commercially launched
in 2019 and are currently distributed through pharmaceutical wholesaler networks in each respective country. They are available at retail
pharmacies as a prescription-only malaria prevention drug. According to the Centers for Disease Control and Prevention, the long
terminal half-life of tafenoquine, which is approximately 16 days, may offer potential advantages in less-frequent dosing
for prophylaxis for malaria. ARAKODA is not suitable for everyone, and patients and prescribers should review the Important
Safety Information below. Individuals at risk of contracting malaria are prescribed ARAKODA 2 x 100 mg tablets once per day for three
days (the loading phase) prior to travel to an area of the world where malaria is endemic, 2 x 100 mg tablets weekly for up to six months
during travel, then 2 x 100 mg in the week following travel.
ARAKODA® (tafenoquine) Important Safety
Information
ARAKODA® is an antimalarial indicated
for the prophylaxis of malaria in patients aged 18 years of age and older.
Contraindications
ARAKODA® should not be administered to:
| 1. | Glucose-6-phosphate dehydrogenase (“G6PD”) deficiency
or unknown G6PD status; |
| 2. | Breastfeeding by a lactating woman when the infant is found
to be G6PD deficient or if G6PD status is unknown; |
| 3. | Patients with a history of psychotic disorders or current psychotic
symptoms; or |
| 4. | Known hypersensitivity reactions to tafenoquine, other
8-aminoquinolines, or any component of ARAKODA®. |
Warnings and Precautions
Hemolytic Anemia: G6PD testing must be performed before prescribing
ARAKODA® due to the risk of hemolytic anemia. Monitor patients for signs or symptoms of hemolysis.
G6PD Deficiency in Pregnancy or Lactation: ARAKODA® may
cause fetal harm when administered to a pregnant woman with a G6PD-deficient fetus. ARAKODA® is not recommended during pregnancy.
A G6PD-deficient infant may be at risk for hemolytic anemia from exposure to ARAKODA® through breast milk. Check infant’s G6PD
status before breastfeeding begins.
Methemoglobinemia: Asymptomatic elevations in blood methemoglobin
have been observed. Initiate appropriate therapy if signs or symptoms of methemoglobinemia occur.
Psychiatric Effects: Serious psychotic adverse reactions have
been observed in patients with a history of psychosis or schizophrenia at doses different from the approved dose. If psychotic symptoms
(hallucinations, delusions, or grossly disorganized thinking or behavior) occur, consider discontinuation of ARAKODA® therapy and
evaluation by a mental health professional as soon as possible.
Hypersensitivity Reactions: Serious hypersensitivity reactions
have been observed with administration of ARAKODA®. If hypersensitivity reactions occur, institute appropriate therapy.
Delayed Adverse Reactions: Due to the long half-life of ARAKODA®
(approximately 16 days), psychiatric effects, hemolytic anemia, methemoglobinemia, and hypersensitivity reactions may be delayed in onset
and/or duration.
Adverse Reactions: The most common adverse reactions (incidence
greater than or equal to 1 percent) were: headache, dizziness, back pain, diarrhea, nausea, vomiting, increased alanine aminotransferase,
motion sickness, insomnia, depression, abnormal dreams, and anxiety.
Drug Interactions
Avoid co-administration with drugs that are substrates of organic cation
transporter-2 or multidrug and toxin extrusion transporters.
Use in Specific Populations
Lactation: Advise women not to breastfeed a G6PD-deficient infant or
infant with unknown G6PD status during treatment and for three months after the last dose of ARAKODA®.
To report SUSPECTED ADVERSE REACTIONS,
contact 60 Degrees Pharmaceuticals, Inc. at 1- 888-834-0225 or the FDA at 1-800-FDA-1088
or www.fda.gov/medwatch. The full prescribing information for ARAKODA® is located here.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing
and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees
Pharmaceuticals, Inc. achieved FDA approval for its lead product, ARAKODA® (tafenoquine), for malaria prevention in 2018. 60
Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees
Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional
investors, including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals,
Inc. is headquartered in Washington, D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com.
The statements contained herein may include prospects, statements of
future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve
known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied
in such forward-looking statements.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain “forward-looking statements”
within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements
reflect the current view about future events. When used in this press release, the words “anticipate,” “believe,”
“estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these
terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Forward-looking statements
are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and
assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy,
activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future,
they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside
of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements.
Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial
condition to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial
doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development
tax rebates; if we are not able to successfully develop, obtain FDA approval for, and provide for the commercialization of non- malaria
prevention indications for tafenoquine (ARAKODA® or other regimen) or Celgosivir in a timely manner, we may not be able to
expand our business operations; we may not be able to successfully conduct planned clinical trials or patient recruitment in our trials
might be slow or negligible; and we have no manufacturing capacity which puts us at risk of lengthy and costly delays of bringing our
products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking
statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including
the information contained in our Annual Report on Form 10-K filed with the SEC on April 1, 2024, and our subsequent SEC filings. Investors
and security holders are urged to read these documents free of charge on the SEC’s website at www.sec.gov. As a result of these
matters, changes in facts, assumptions not being realized or other circumstances, the Company’s actual results may differ materially
from the expected results discussed in the forward-looking statements contained in this press release. Any forward-looking statement made
by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made.
We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time,
whether as a result of new information, future developments or otherwise.
END
Media Contact:
Sheila A. Burke
SheilaBurke-consultant@60degreespharma.com
(484) 667-6330
Investor Contact:
Patrick Gaynes
patrickgaynes@60degreespharma.com
(310) 989-5666
Tags:
#sxtp
#malaria
5
v3.24.2.u1
Cover
|
Aug. 12, 2024 |
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Aug. 12, 2024
|
Entity File Number |
001-41719
|
Entity Registrant Name |
60 DEGREES PHARMACEUTICALS, INC.
|
Entity Central Index Key |
0001946563
|
Entity Tax Identification Number |
45-2406880
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
1025 Connecticut Avenue NW
|
Entity Address, Address Line Two |
Suite 1000
|
Entity Address, City or Town |
Washington
|
Entity Address, State or Province |
DC
|
Entity Address, Postal Zip Code |
20036
|
City Area Code |
202
|
Local Phone Number |
327-5422
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
Common Stock, par value $0.0001 per share |
|
Title of 12(b) Security |
Common Stock, par value $0.0001 per share
|
Trading Symbol |
SXTP
|
Security Exchange Name |
NASDAQ
|
Warrants, each warrant to purchase one share of Common Stock |
|
Title of 12(b) Security |
Warrants, each warrant to purchase one share of Common Stock
|
Trading Symbol |
SXTPW
|
Security Exchange Name |
NASDAQ
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14a -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=SXTP_CommonStockParValue0.0001PerShareMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
X |
- Details
Name: |
us-gaap_StatementClassOfStockAxis=SXTP_WarrantsEachWarrantToPurchaseOneShareOfCommonStockMember |
Namespace Prefix: |
|
Data Type: |
na |
Balance Type: |
|
Period Type: |
|
|
60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Historical Stock Chart
From Jul 2024 to Aug 2024
60 Degrees Pharmaceuticals (NASDAQ:SXTP)
Historical Stock Chart
From Aug 2023 to Aug 2024